Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 10/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622410 | 0.82 | ADRB3 (0.36) | ADRB3ADRB1BCL2L1IRAK4HTR2A | |
| SCHEMBL4584315 | 0.82 | ADRB1 (0.42) | ADRB3ADRB1SCN9A | |
| SCHEMBL1622644 | 0.80 | BCL2L1 (0.36) | ADRB3ADRB1BCL2L1SCN9AIRAK4 | |
| SCHEMBL4585947 | 0.79 | SCN9A (0.56) | ADRB3ADRB1SCN9A | |
| SCHEMBL4582967 | 0.79 | SCN9A (0.43) | ADRB3ADRB1SCN9A | |
| SCHEMBL5703690 | 0.78 | ADRB3 (0.46) | ADRB3ADRB1BCL2L1SCN9AIRAK4 | |
| SCHEMBL4583898 | 0.72 | ADRB3 (0.66) | ADRB3ADRB1 | |
| SCHEMBL5704207 | 0.70 | ADRB3 (0.63) | ADRB3ADRB1 | |
| SCHEMBL29954406 | 0.69 | CA2 (0.39) | IRAK4 | |
| SCHEMBL29954995 | 0.67 | TTR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB3 86/4885ADRB1 70/4885BCL2L1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.